The minimal residual disease (MRD) testing market registered high‑impact trial readouts and commercial consolidation in 2025, anchored by positive Phase III IMvigor011 results using Natera’s Signatera assay to select muscle‑invasive bladder cancer patients for adjuvant atezolizumab. Signatera‑positive patients on Tecentriq showed statistically significant survival improvements, per presentations at the European Society for Medical Oncology. Natera is preparing a premarket application to the FDA to qualify Signatera as a companion diagnostic for adjuvant checkpoint therapy. The IMvigor011 readout is being viewed by clinicians and guideline bodies as one of the first randomized confirmations that ctDNA‑guided adjuvant therapy can alter outcomes in a solid tumor. The year also saw acquisitions and reimbursement wins that validate MRD as a clinically actionable biomarker — stakeholders will monitor regulatory submissions, guideline uptake and payor coverage as determinants of commercial scale.